CRISPR-engineered peanuts aim to ease allergy restrictions in public venues

Bryant Williams, chief executive of Minnesota-based Nurtured Nuts, has engineered a peanut that omits three proteins—RH2, RH6 and RH7—known to cause serious allergic responses. The modified seed, produced with CRISPR technology, is not intended for people with severe peanut allergies but is designed to reduce risk in shared environments such as cafeterias and flights. A clinical study underway at a major hospital is measuring how allergic individuals react to the new peanuts versus traditional ones.

The USDA granted permission to grow the seeds in Georgia in late 2025, and the company is pursuing FDA approval, which could be granted by 2027. Potential market entry points include restaurants, schools and hospitals, though timelines remain uncertain as Nurtured Nuts negotiates with various partners. The innovation also opens possibilities for using the nuts in oil, flour, butter and even non-food products like cosmetics and building materials, though consumer acceptance of a genetically modified food may pose a challenge.